Juriste Foncier (H / F)

Description de poste

Topic description

Lung pathologies are still challenging to diagnose and treat, despite advancements. Computed tomography (CT) is now the most effective clinical imaging method, yet it has a number of drawbacks. Spectral photon counting Scanner (SPCCT) is a new imaging modality with advantages over CT and has demonstrated its interest for lung pathologies. However, new contrast agents must be formulated in order to fully use the capabilities of SPCCT and improve lung imaging. In addition to the need for better monitoring of lung diseases, better therapy is also required. Indeed, the administration of drugs in the lungs faces the problem of crossing different physiological barriers that limit the delivery of therapeutic actives to the target areas in sufficient doses while limiting the adverse effects.

Nanosystems are of diverse interest for pulmonary drug delivery. They can improve drug stability and solubility, lead to targeting and controlled and sustained release, protect pulmonary clearance mechanisms, and improve drug delivery. The goal of this project is to develop a nanoplatform for simultaneous efficient SPCCT imaging contrast and drug delivery. The combination of contrast agents with therapeutic agents would allow the quantification of the delivered dose of the active agent, the study of its distribution in the lungs, and the monitoring of the effectiveness of the treatments.

The major part of the PhD will consist of the formulation of nanoparticles. After formulation, the physicochemical properties will be studied (size, drug encapsulation and release, stability, interactions with biomolecules, etc.). Various analytical techniques will be used in collaboration with ICSM (CEA, France). Toxicity of formulations will also be evaluated on cell models of interest. In vitro and in vivo imaging efficiency will be evaluated in collaboration with cardiovascular radiologists (CREATIS lab, Lyon) on small animals. The PhD student will be trained for in vitro and in vivo work if necessary.

Starting date

• 01-01

Funding category

Other public funding

Funding further details

Financement déjà acquis.